Sign in

GBIM on NASDAQ

GlobeImmune

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform.3 It was founded in 1995.1 Its shares trade on NASDAQ under the symbol GBIM.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 1995Founded1

Compare with another stock.

  • TickerGBIM on NASDAQ1
  • Industrybiotechnology1
  • HeadquartersLouisville1
  • Websitewww.globeimmune.com
  • Incorporated inDE4
  • Business address1450 Infinite Drive, Louisville, Co 800274
  • Filer categorySmaller reporting company4

See how the biggest companies compare on our leaderboards

Labeled tarmogen MOA
Photo: CC-BY-SA-3.0, via Wikipedia5

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.3

What it owns

What GlobeImmune reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.0M6 Dec 31, 2015$12.3M6 Dec 31, 2014−18.4%
Accumulated depreciation$9.8M6 Dec 31, 2015$11.8M6 Dec 31, 2014−17.0%
Property and equipment, net$209.7K6 Dec 31, 2015$455.8K6 Dec 31, 2014−54.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.9M6 Dec 31, 2015$16.8M6 Dec 31, 2014−41.1%

Leadership

Who has led GlobeImmune, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Timothy C. Rodell Jr.2014–2015
200020052010201520202025
Board members and other officers (8)

Timeline

  1. Jul 1, 2014New chief executive Timothy C. Rodell Jr. becomes CEO7
  2. Jan 1, 1995Founded Founded1

SEC filer profile

How GlobeImmune is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGLOBEIMMUNE INC2
  • CIK0001245104
  • Employer ID (EIN)84-13539252
  • Filer statusSmaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address1450 Infinite Drive, Louisville, CO 800272
  • Phone30362527442
  • Shares outstanding5,751,574 as of Apr 29, 201615
  • Public float$8.5M as of Jun 30, 20156
  • On EDGAR sinceJun 20, 20032
  • Filings153 in all: 4 (36), 8-K (23), 3 (10), S-1/A (9), REGDEX/A (7), 10-Q (6), D (6), SC 13G (5)2
    All 34 form types

    CT ORDER (4), REGDEX (4), CERTNAS (3), CORRESP (3), FWP (3), SC 13G/A (3), UPLOAD (3), 10-K (2), 10-K/A (2), 3/A (2), 4/A (2), 8-A12B (2), D/A (2), S-1 (2), S-8 (2), S-8 POS (2), 10-Q/A (1), 15-12B (1), 25 (1), 424B4 (1), DEF 14A (1), DEFA14A (1), EFFECT (1), POS EX (1), RW (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2016
    Quarterly report (10-Q) May 12, 2016
    Proxy statement (DEF 14A) May 22, 2015
    Latest 8-K (8-K) Jul 5, 2016

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15